Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Regeneron pharmaceuticals, inc. save search
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Published: 2024-02-21 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.54%
H: 0.63%
C: 0.09%
fda review treatment
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
Published: 2024-02-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -2.68%
treatment ema
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -1.82%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.33%
H: 0.65%
C: -1.26%
dupixent fda first children approved year treatment
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
libtayo cell treatment
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
Published: 2023-10-03 (Crawled : 11:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.74%
H: 0.21%
C: -0.45%
NTLA | $21.535 -1.35% -1.37% 850K
|
Health Technology
|
| O: -0.1%
H: 1.97%
C: 1.02%
treatment research collaboration neurological
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
Published: 2023-09-29 (Crawled : 13:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.64%
H: 0.04%
C: -0.57%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.13%
H: 0.02%
C: -1.26%
fda review treatment
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Published: 2023-09-25 (Crawled : 21:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: 0.46%
H: 4.26%
C: 1.55%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
evkeeza treatment hypercholesterolemia canada
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
Published: 2023-08-23 (Crawled : 14:00) - biospace.com/
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.52%
H: 0.3%
C: -0.5%
disease treatment
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
Published: 2023-08-18 (Crawled : 23:00) - globenewswire.com
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
fda eylea macular approved treatment injection diabetic
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
Published: 2023-08-18 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.39%
H: 3.29%
C: 2.21%
fda disease children approval treatment
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.95%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: 0.0%
treatment ema
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published: 2023-03-29 (Crawled : 12:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.37%
H: 0.6%
C: -1.28%
libtayo lung approved positive cancer cell treatment
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Published: 2023-03-07 (Crawled : 07:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.21%
H: 0.2%
C: -1.04%
dupixent treatment fda urticaria application review
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
Published: 2023-03-07 (Crawled : 07:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.21%
H: 0.2%
C: -1.04%
dupixent treatment fda urticaria application review
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published: 2023-02-24 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.11%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.77%
H: 1.52%
C: 0.42%
libtayo treatment lung chmp positive cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.